BMY published the Phase 2 trial results in NEJM. I have not seen it yet, but there are reports of the results. The trial is analogous to the Vertex's Zenith trial except BMY chose to treat patients who were null non-responders (I am still waiting for NEJM to confirm this) to previous SOC(the Boomberg news piece below skips this fact). You will notice that their all-oral two drug result is much inferior (=36%) to their quad therapy(with pegIFN + RBV, =90%).
I read the article in the NEJM. It underscores the possible necessity of using multiple drugs to treat resistant genotype 1, including the NS3 class (protease inhibitors. So, it is likely that telapravir and other PI's will not become obsolete in the near future.
The goal is still high cure rate IFN free regimens. That's the ideal treatment that the street is really rewarding, and that is why 90% SVR Quad results aren't helping stock movement for Vertex or BMY.